Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy during Screening period.~* Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the Investigator, with oral corticosteroids or immunosuppressants or both. Mayo Score is confirmed by central reader.~Exclusion Criteria:~* Subject with Crohn's disease (CD) or indeterminate colitis (IC).~* Current diagnosis of fulminant colitis and/or toxic megacolon.~* Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.~* Chronic recurring infections or active tuberculosis (TB).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Induction (Main Study + Japan Sub-study): I-SD (Type: EXPERIMENTAL): Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
- Induction (Main Study + Japan Sub-study): I-HD (Type: EXPERIMENTAL): Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
- Maintenance (Main Study + Japan Sub-study): M-SD (Type: EXPERIMENTAL): Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
- Maintenance (Main Study + Japan Sub-study): M-HD (Type: EXPERIMENTAL): Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
- Maintenance (Main Study): TDM Regimen (Type: EXPERIMENTAL): Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).